Adtalem Global Education Lifts Guidance on Solid Q3

Adtalem Global Education ((CVSA)) has held its Q3 earnings call. Read on for the main highlights of the call.

Adtalem Global Education’s latest earnings call struck an upbeat tone, with management emphasizing broad-based momentum despite some temporary headwinds. Adjusted for a one-week timing shift at Walden, the company showed faster revenue growth, expanding margins, rising earnings and robust cash generation, giving investors confidence that the growth story is intact.

Revenue Growth and Raised Guidance

Adtalem reported Q3 revenue of $487.0 million, up 4.5% year over year, but underlying growth was stronger once a one-week Walden timing shift is excluded, which would have lifted revenue by 8.4%. Management raised full-year revenue guidance to a range of $1.93 billion to $1.945 billion, implying 8% to 9% growth heading into fiscal 2026.

Improved Profitability and EPS Upside

Consolidated adjusted EBITDA reached $127.9 million, and would have been $145.9 million, a 14.2% increase, without the Walden timing impact, underscoring healthy operating leverage. The company also raised adjusted EPS guidance to $7.95 to $8.15, signaling 19% to 22% growth versus last year and reinforcing the earnings momentum narrative.

Strong Enrollment Momentum Across the Platform

Adtalem said it surpassed 100,000 total students and delivered its eleventh straight quarter of total enrollment growth, highlighting the durability of demand across its portfolio. Walden enrollment jumped 12.3% to a record 54,474 students, Chamberlain returned to growth with enrollment up 0.5% to 40,767, and Med/Vet programs grew 4.1% to 5,344 students.

Segment-Level Operational Strength

Walden’s underlying performance was particularly strong, with revenue up 14.7% and adjusted EBITDA up 25.5% excluding the timing shift, pushing its margin to 33.1%, up 280 basis points. Med & Vet posted revenue growth of 8.9% to $103.5 million and adjusted EBITDA growth of 20.1% to $27.5 million, while Chamberlain’s margin edged up 20 basis points to 29.7% as adjusted EBITDA rose 2.9%.

Cash Generation, Balance Sheet and Capital Allocation

Trailing 12-month free cash flow increased 17% to $336 million, giving Adtalem substantial financial flexibility to fund growth and return capital. Net leverage fell to 0.7 times, cash and equivalents stood at $147 million, the company refinanced a $510 million term loan at a lower rate to 2033, and it repurchased $66 million of stock during the quarter.

Operational and Academic Outcomes

Management highlighted operational improvements, including cutting application review times by weeks through process changes and automation, which should improve conversion and student experience. Academic outcomes remain a core selling point, with a 97% first-time residency attainment rate, AUC above 98% and veterinary placement results among the top in the United States.

Growth Initiatives: Campus Expansion and New Programs

Adtalem is investing in capacity, with six new Chamberlain campuses in active development, the first of which is set to begin teaching in September and two already gaining regulatory approval. Walden is broadening its academic portfolio, having launched new programs in clinical psychology and behavioral analysis that already enrolled more than 1,400 students, alongside seven additional program approvals.

AI and Technology Partnerships

The company is leaning into technology by co-developing an AI-powered classroom with Google Cloud, with pilots scheduled for later this year, signaling a push to differentiate its learning experience. Over 4,000 learners have enrolled in new AI-related credentials across nursing, medicine and foundational AI, supported by Covista’s Healthcare Readiness AI Council to keep curricula grounded in clinical practice.

Walden One-Week Academic Calendar Timing Impact

A notable one-week shift in Walden’s academic calendar moved about $18 million of revenue into Q2 from Q3, which materially depressed reported Q3 revenue, adjusted EBITDA and EPS. Management stressed that excluding this timing issue, consolidated revenue would have grown 8.4%, adjusted EBITDA would have been $145.9 million and margin 28.9%, underscoring stronger underlying performance.

Chamberlain Enrollment Still Modest This Quarter

Chamberlain’s return to positive total enrollment growth was a key milestone, but the 0.5% year-over-year gain in Q3 was modest, and management was careful not to overstate the progress. They acknowledged prior execution issues in marketing and funnel conversion, signaling that more work remains before they can declare a full turnaround in that business.

Post-Licensure (RN to BSN) Headwinds

Pre-licensure programs at Chamberlain continued to perform, marking their fifteenth consecutive quarter of growth and helping stabilize enrollment. However, post-licensure programs, particularly RN to BSN, were lower in the quarter, with management noting that this category is structurally less robust than several years ago even though Chamberlain still leads the space.

Increased Strategic Investments and Near-Term CapEx Ramp

Adtalem flagged that targeted strategic growth investments in the fourth quarter and a ramp in capital expenditures will pressure near-term margins as it funds campus expansion and new initiatives. CapEx climbed from $31 million in the first half to $20 million in Q3 alone, with management signaling further increases in Q4, but they framed this as necessary spending to support long-term growth.

Higher Effective Tax Rate Expectation

Management cautioned that they expect an effective tax rate higher than in fiscal 2025, which could modestly weigh on net income and EPS compared with prior assumptions. Even so, the raised EPS guidance suggests that strong operating performance and cost discipline should more than offset the drag from higher taxes.

Limited Public Detail on Employer Partnerships

Employer partnerships were mentioned as encouraging proof points, including existing relationships that demonstrate the potential for enterprise demand, but management offered limited new disclosure this quarter. They indicated that pipeline conversations continue, yet no major new deals or commercialization metrics were announced, leaving this as a longer-term upside lever rather than a near-term catalyst.

Forward-Looking Guidance and Outlook

Looking ahead, Adtalem’s raised revenue and EPS guidance, along with a targeted 100 basis point expansion in fiscal 2026 adjusted EBITDA margin, signal confidence in continued growth despite tax and investment headwinds. Management expects Chamberlain enrollment trends in Q4 to mirror Q3, continues to execute on strategic investments and campus expansion, and is backed by $336 million of trailing free cash flow, $147 million in cash and low leverage.

Adtalem’s earnings call painted a picture of a company balancing strong current execution with deliberate investment for future growth, even as it navigates timing quirks, modest Chamberlain gains and a higher tax outlook. For investors, the combination of raised guidance, widening margins, solid enrollment trends and disciplined capital allocation suggests the education provider remains on a constructive trajectory.